Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 2/20 | 0.55 |
| ▸ | ITGAV | P06756 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.40 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.38 |
| ▸ | TACR3 | P29371 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13595659 | 0.92 | ITGB1 (0.61) | ITGB1ITGAVCDK2ITGA4ITGB7 | |
| SCHEMBL3312947 | 0.91 | ITGB1 (0.67) | ITGB1ITGAVCDK2CCNA2CCNA1 | |
| SCHEMBL3318313 | 0.86 | ITGB1 (0.49) | ITGB1ITGAVMCHR1CHRM2 | |
| SCHEMBL14302839 | 0.84 | ITGB1 (0.60) | ITGB1ITGAVCDK2CCNA2CCNA1 | |
| SCHEMBL3319924 | 0.82 | ITGB1 (0.80) | ITGB1ITGAVCDK2ITGA4ITGB7 | |
| SCHEMBL8353596 | 0.82 | ITGB1 (0.80) | ITGB1ITGAVCDK2ITGA4ITGB7 | |
| SCHEMBL3315770 | 0.82 | ITGB1 (0.80) | ITGB1ITGAVCDK2ITGA4ITGB7 | |
| SCHEMBL4625157 | 0.80 | ITGB1 (0.59) | ITGB1ITGAVCDK2ITGA4ITGB7 | |
| SCHEMBL13398361 | 0.79 | ITGB1 (0.53) | ITGB1ITGAVITGA4ITGB7ABL1 | |
| SCHEMBL1028109 | 0.79 | ITGB1 (0.72) | ITGB1ITGAVCDK2ITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105681-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | LASSOIE MARIE-AGNES | 2010-04-29 | — | — | US | disclosed |
| US-20100105681-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | LASSOIE MARIE-AGNES | 2010-04-29 | — | — | US | disclosed |
| EP-1501801-B1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF VLA-4 DEPENDENT DISEASES | UCB PHARMA SA (BE) | 2008-01-23 | — | — | EP | disclosed |
| WO-2003093237-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | UCB, S.A. (BE) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105681-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | SCN4A, NECTIN4, VPS4B | ITGB1 274/4885ITGAV 65/4885CDK2 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.